Treo Ventures

SecondWave Systems develops an ultrasound stimulation platform that will give patients and their physicians a new option for treating debilitating or life-threatening diseases. Their technology utilizes non-invasive, low-intensity focused ultrasound to modulate nerves, cells, and organs deep within the body. They provide technology that suppresses neural and cellular pathways with the potential to treat many conditions, including inflammation, pain, and a variety of other disorders.

InterVene, Inc. is a medical device company based in South San Francisco, California, that specializes in innovative catheter-based therapies for chronic venous insufficiency (CVI), particularly addressing deep vein valve failure. Established in 2011, InterVene has developed the BlueLeaf™ Endovenous Valve Formation System, a non-implantable solution aimed at treating severe venous conditions. The company's devices enable healthcare professionals to create new vein valves from the patient's own vein wall tissue, improving blood flow from the legs back to the heart. By focusing on minimally invasive treatments, InterVene seeks to enhance patient outcomes for those suffering from venous stasis ulcers and associated symptoms.

ShiraTronics, Inc. is a company that specializes in developing and commercializing neuromodulation therapies aimed at treating chronic migraines, a condition that significantly impacts the lives of millions worldwide. Founded in 2018 and headquartered in Ireland, with an additional location in Minneapolis, Minnesota, ShiraTronics is focused on addressing unmet clinical needs in neurology. The company's innovative technologies offer new approaches to effectively alleviate the debilitating effects of migraine headaches, thereby striving to improve the quality of life for those affected by this disabling disorder.

NeuSpera Medical Inc. specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy, focusing on treating chronic illnesses through minimally invasive solutions. The company utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to direct energy to the implants. This innovative approach allows for external powering of the devices, facilitating deeper and more reliable neuromodulation treatments for conditions such as Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain. Founded in 2013 and based in San Jose, California, NeuSpera Medical is committed to advancing bioelectronic medicine.

iVEAcare focuses on developing innovative neuromodulation therapies aimed at addressing unmet clinical needs in the treatment of chronic diseases. The company creates advanced devices and software that provide targeted electrical stimulation to specific regions of the brain or spinal cord. This technology allows medical professionals to design therapies that are not only more effective but also less invasive than conventional treatments, thereby expanding access to a broader patient population.

Noctrix Health, Inc. is an early-stage medical device company based in Menlo Park, California, founded in 2018. The company specializes in developing therapeutic wearable devices aimed at treating chronic neurological and sleep disorders, particularly focusing on restless leg syndrome. Its innovative device utilizes neural circuitry to alleviate symptoms and promote undisturbed sleep, empowering patients to better manage their chronic medical conditions.

NeuSpera Medical Inc. specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy, focusing on treating chronic illnesses through minimally invasive solutions. The company utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to direct energy to the implants. This innovative approach allows for external powering of the devices, facilitating deeper and more reliable neuromodulation treatments for conditions such as Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain. Founded in 2013 and based in San Jose, California, NeuSpera Medical is committed to advancing bioelectronic medicine.

Noctrix Health, Inc. is an early-stage medical device company based in Menlo Park, California, founded in 2018. The company specializes in developing therapeutic wearable devices aimed at treating chronic neurological and sleep disorders, particularly focusing on restless leg syndrome. Its innovative device utilizes neural circuitry to alleviate symptoms and promote undisturbed sleep, empowering patients to better manage their chronic medical conditions.

CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.

ShiraTronics, Inc. is a company that specializes in developing and commercializing neuromodulation therapies aimed at treating chronic migraines, a condition that significantly impacts the lives of millions worldwide. Founded in 2018 and headquartered in Ireland, with an additional location in Minneapolis, Minnesota, ShiraTronics is focused on addressing unmet clinical needs in neurology. The company's innovative technologies offer new approaches to effectively alleviate the debilitating effects of migraine headaches, thereby striving to improve the quality of life for those affected by this disabling disorder.

NeoChord, Inc. is a medical technology company based in St. Louis Park, Minnesota, that focuses on developing innovative devices for the treatment of degenerative mitral valve disease (DMR). Founded in 2007, the company has created the NeoChord Artificial Chordae Delivery System, a disposable device designed for minimally invasive mitral valve repair. This system allows surgeons to replace damaged chordae through a small incision of 2 to 3 inches between the ribs, enabling the procedure to be performed on a beating heart. This approach contrasts sharply with traditional methods, which typically involve larger incisions and stopping the heart, thus reducing recovery time and associated complications. NeoChord's technology aims to improve surgical outcomes for patients suffering from severe mitral regurgitation, which can lead to serious conditions such as atrial fibrillation and congestive heart failure.

Hyalex Orthopaedics, Inc. is a medical device company based in Lexington, Massachusetts, focused on developing innovative products that utilize HYALEX technology, a synthetic polymer engineered to mimic cartilage. Founded in 2016, the company specializes in creating a biomimetic material that can effectively simulate healthy cartilage to treat diseased or damaged joints. The unique properties of HYALEX allow it to maintain low friction and wear, even under the significant loads typically experienced in human joints. This capability enables surgeons to replace arthritic cartilage while preserving healthy bone. Although Hyalex Orthopaedics is advancing its product development, its offerings have not yet received approval for use in humans from any regulatory agency.